유방암 조직에서 ATP를 이용한 항암제 반응성 검사의 유용성 = Heterogeneous Chemosensitivity of Breast Cancer Determined by Adeonsine Triphosphate Based Chemotherapy Response Assay

다국어 초록 (Multilingual Abstract)

Purpose: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. Methods: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. Results: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin was higher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p=0.114, p=0.311, respectively). Conclusion: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective randomized controlled trial should be preceded.

참고문헌 (Reference)

1 Kurbacher CM, "Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer" 9 : 51-57, 1998

2 Kawamura H, "The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer" 33 : 960-966, 1997

3 Maenpaa JU, "The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial" 57 : 294-298, 1995

4 Myatt N, "The ex vivo chemosensitivity profile of choroidal melanoma" 8 : 756-762, 1997

5 Maehara Y, "The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability" 23 : 273-276, 1987

6 Cortazar P, "Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing" 3 : 741-747, 1997

7 Von Hoff DD, "Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician" 82 : 110-116, 1990

8 Cortazar P, "Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer" 17 : 1625-1631, 1999

9 Dieras V, "Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer" 22 : 4958-4965, 2004

10 Von Hoff DD, "Prospective clinical trial of a human tumor cloning system" 43 : 1926-1931, 1983

11 O’Meara AT, "Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer" 83 : 334-342, 2001

12 Xu JM, "Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro" 53 : 77-85, 1999

13 Sharma S, "Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma" 3 : 19-, 2003

14 Eifel P, "National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer" 93 : 979-989, 2001

15 Breidenbach M, "Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay" 11 : 269-273, 2000

16 Breidenbach M, "Individualized long-term chemotherapy for recurrent ovarian cancer after failing highdose treatment" 13 : 173-176, 2002

17 Shaw GL, "Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing" 53 : 5181-5187, 1993

18 Cree IA, "Heterogeneity of chemosensitivity of metastatic cutaneous melanoma" 10 : 437-444, 1999

19 Honkoop AH, "Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer" 107 : 211-218, 1997

20 Cree IA, "Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity" 7 : 630-635, 1996

21 Shaw GL, "Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer" 24 : 173-185, 1996

22 Konecny G, "Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer" 77 : 258-263, 2000

23 Petty RD, "Comparison of MTT and ATP-based assays for the measurement of viable cell number" 10 : 29-34, 1995

24 Ng TY, "Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples" 76 : 405-408, 2000

25 Wilbur DW, "Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill" 65 : 27-32, 1992

26 Andreotti PE, "Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma" 55 : 5276-5282, 1995

27 Haskell CM, "Cancer Treatment. 5th ed" W.B. Saunders 2001

28 Devita VT, "Cancer Principles & Practice of Oncology. 6th ed" Lippincott Williams & Wilkins 2001

29 Daidone MG, "Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer" 84 : 580-586, 1999

30 Koechli OR, "Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results" 54 : 119-125, 1993

31 Sevin BU, "Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing" 31 : 191-204, 1988

32 Sjostrom J, "A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer" 78 : 812-815, 1998

33 Von Hoff DD, "A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer" 67 : 20-27, 1991